|
covid-19 |
45 |
|
public health |
26 |
|
stroke |
26 |
|
type 2 diabetes mellitus |
26 |
|
dementia |
20 |
|
myocardial infarction |
20 |
|
coronary artery disease |
19 |
|
medical sciences |
17 |
|
healthcare workers |
16 |
|
hospital policies |
16 |
|
perceived stress |
16 |
|
psychological wellbeing |
16 |
|
hypertension |
15 |
|
ischemic stroke |
15 |
|
risk prediction |
15 |
|
atrial fibrillation |
14 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
sars-cov-2 |
14 |
|
blood pressure |
13 |
|
intracerebral hemorrhage |
13 |
|
chronic diseases |
12 |
|
health services |
12 |
|
non-communicable diseases |
12 |
|
health economics |
11 |
|
intracranial hemorrhage |
11 |
|
primary care |
11 |
|
risk factor |
11 |
|
secondary prevention |
11 |
|
adipocyte |
10 |
|
adverse events |
10 |
|
b-type natriuretic peptide |
10 |
|
blood pressure variability |
10 |
|
cardiac troponin |
10 |
|
covid-19 vaccine |
10 |
|
delirium |
10 |
|
fibroblast growth factor |
10 |
|
lipocalin-2 |
10 |
|
vaccine safety |
10 |
|
carotid intima-media thickness |
9 |
|
endothelial function |
9 |
|
female |
9 |
|
garlic |
9 |
|
humans |
9 |
|
male |
9 |
|
recurrence |
9 |
|
vascular function |
9 |
|
aerosolised |
8 |
|
anosmia |
8 |
|
cardiovascular and cerebrovascular diseases |
8 |
|
cha2ds2-vasc |
8 |
|
chads2 |
8 |
|
endothelial dysfunction |
8 |
|
endothelial progenitor cells |
8 |
|
follow-up studies |
8 |
|
functional brain network |
8 |
|
hemoglobin a1c |
8 |
|
indirect effect |
8 |
|
long covid |
8 |
|
meta-analysis |
8 |
|
middle aged |
8 |
|
mortality |
8 |
|
olfactory dysfunction |
8 |
|
olfactory training |
8 |
|
prognosis |
8 |
|
resting-state fmri |
8 |
|
risk factors |
8 |
|
smell loss |
8 |
|
systematic review |
8 |
|
vascular markers |
8 |
|
vascular markers of atherosclerosis |
8 |
|
vitamin a |
8 |
|
warfarin |
8 |
|
25-hydroxyvitamin d |
7 |
|
antiplatelet medication |
7 |
|
cha2ds2-vasc score |
7 |
|
chads2 score |
7 |
|
circulating endothelial progenitor cells |
7 |
|
covid-19 pandemic |
7 |
|
cutoff |
7 |
|
epidemiology |
7 |
|
hematoma location |
7 |
|
hong kong |
7 |
|
intracranial hemorrhages |
7 |
|
isoflavone |
7 |
|
lacunar infarct |
7 |
|
physical activity |
7 |
|
pleiotropic effects |
7 |
|
pr prolongation |
7 |
|
school closures |
7 |
|
school-aged children |
7 |
|
screen time |
7 |
|
sleep |
7 |
|
statin therapy |
7 |
|
stroke outcome |
7 |
|
adverse cardiovascular events |
6 |
|
adverse cardiovascular outcomes |
6 |
|
age factors |
6 |
|
aged |
6 |
|
alff |
6 |
|
antiplatelet agents |
6 |
|
arterial stiffiness |
6 |
|
aspirin - administration & dosage - adverse effects |
6 |
|
atrioventricular block - complications - diagnosis - physiopathology |
6 |
|
brachial artery - physiopathology - ultrasonography |
6 |
|
cardiovascular continuum |
6 |
|
cardiovascular death |
6 |
|
cardiovascular diseases - blood - diet therapy - prevention & control |
6 |
|
cardiovascular diseases - etiology - physiopathology |
6 |
|
cardiovascular event |
6 |
|
cerebral small vessel disease |
6 |
|
cerebrovascular event |
6 |
|
chads2 and cha2ds2-vasc scores |
6 |
|
chronic kidney disease |
6 |
|
data repository |
6 |
|
diet |
6 |
|
dietary supplements |
6 |
|
diffusivity |
6 |
|
dti |
6 |
|
electrocardiography |
6 |
|
endothelial cells - cytology - physiology |
6 |
|
endothelium, vascular - cytology - physiology |
6 |
|
flow cytometry |
6 |
|
functional connectivity |
6 |
|
functional mri |
6 |
|
has-bled score |
6 |
|
high-sensitivity troponin i |
6 |
|
ich volume |
6 |
|
intracranial hemorrhages - drug therapy - physiopathology - surgery |
6 |
|
intraventricular extension |
6 |
|
mediterranean-style diet |
6 |
|
meta-data |
6 |
|
multimodal |
6 |
|
myocardial injury |
6 |
|
neurogen |
6 |
|
neurological and mental health global epidemiology network |
6 |
|
neurological deterioration |
6 |
|
parkinson's disease |
6 |
|
pathophysiological mechanism |
6 |
|
phytoestrogen |
6 |
|
phytoestrogens - administration & dosage |
6 |
|
platelet aggregation inhibitors - administration & dosage - adverse effects |
6 |
|
pr interval prolongation |
6 |
|
questionnaires |
6 |
|
recurrent stroke |
6 |
|
registries |
6 |
|
resting state |
6 |
|
retrospective studies |
6 |
|
spondyloarthritis |
6 |
|
stem cells - physiology |
6 |
|
stroke/prevention |
6 |
|
treatment outcome |
6 |
|
vascular dysfunction |
6 |
|
vasodilation |
6 |
|
visit-to-visit blood pressure variability |
6 |
|
visual hallucinations |
6 |
|
visual spatial memory |
6 |
|
warfarin-associated ich |
6 |
|
antigens, cd34 - analysis |
5 |
|
arteriosclerosis - etiology - pathology - ultrasonography |
5 |
|
autoimmune encephalitis |
5 |
|
brachial artery - drug effects - physiology |
5 |
|
c-reactive protein |
5 |
|
c-reactive protein - metabolism |
5 |
|
carotid arteries - pathology - ultrasonography |
5 |
|
case-control studies |
5 |
|
cell count |
5 |
|
cerebral microbleed |
5 |
|
cognitive footprints |
5 |
|
donepezil |
5 |
|
electronic medical records |
5 |
|
endothelial cells - pathology |
5 |
|
endothelium, vascular - drug effects |
5 |
|
endothelium, vascular - pathology - ultrastructure |
5 |
|
follow-up |
5 |
|
isoflavones - administration and dosage - therapeutic use |
5 |
|
limbic encephalitis |
5 |
|
machine learning |
5 |
|
magnetic |
5 |
|
memantine |
5 |
|
optic neuritis |
5 |
|
paraneoplastic syndrome |
5 |
|
renal impairment |
5 |
|
resonance imaging |
5 |
|
rivastigmine |
5 |
|
soybean proteins - therapeutic use |
5 |
|
stem cells - pathology |
5 |
|
stroke - pathology |
5 |
|
survivors |
5 |
|
tunica intima - ultrasonography |
5 |
|
tunica media - ultrasonography |
5 |
|
acquired myasthenia gravis |
4 |
|
adult cardiology |
4 |
|
alzheimer’s disease |
4 |
|
analysis of variance |
4 |
|
antidepressants |
4 |
|
aquaporin-4 autoantibodies |
4 |
|
atherosclerosis |
4 |
|
autoimmune |
4 |
|
azathioprine |
4 |
|
blood flow velocity |
4 |
|
blood pressure - drug effects - physiology |
4 |
|
brachial artery - pathology |
4 |
|
cardiovascular diseases - blood - diagnosis - mortality |
4 |
|
cardiovascular diseases - epidemiology - metabolism |
4 |
|
caregiver burden |
4 |
|
caregivers |
4 |
|
carotid arteries - pathology |
4 |
|
causal associations |
4 |
|
classical multiple sclerosis |
4 |
|
clinical outcome |
4 |
|
coronary artery disease - pathology |
4 |
|
coronavirus disease |
4 |
|
diabetes mellitus, type 2 - blood - diagnosis - mortality |
4 |
|
diet surveys |
4 |
|
endothelium, vascular - drug effects - physiology |
4 |
|
family caregivers |
4 |
|
family functioning |
4 |
|
flow-mediated dilation |
4 |
|
high-sensitivity troponin i outcome |
4 |
|
immunosuppressant therapy |
4 |
|
incidence |
4 |
|
inflammatory demyelinating disorders |
4 |
|
isoflavones - administration & dosage |
4 |
|
lipid metabolism - drug effects - physiology |
4 |
|
low‐density lipoprotein cholesterol |
4 |
|
neuromyelitis optica spectrum disorders |
4 |
|
pandemic |
4 |
|
prospective cohort study |
4 |
|
psychiatry and neurology |
4 |
|
qualitative research |
4 |
|
randomized controlled trial |
4 |
|
self-controlled case series studies |
4 |
|
soybean proteins - administration & dosage |
4 |
|
soybeans - chemistry |
4 |
|
stroke rehabilitation |
4 |
|
stroke survivors |
4 |
|
telemedicine |
4 |
|
troponin i - blood |
4 |
|
tunica intima - pathology |
4 |
|
tunica intima - pathology - ultrasonography |
4 |
|
tunica media - pathology - ultrasonography |
4 |
|
two-tier family-oriented intervention |
4 |
|
ankle brachial index |
3 |
|
cerebral microbleeds |
3 |
|
cyclegan |
3 |
|
deep learning |
3 |
|
encephalitis |
3 |
|
flow-mediated dilatation |
3 |
|
nervous system |
3 |
|
pulse wave velocity |
3 |
|
quantitative susceptibility mapping |
3 |
|
resnet |
3 |
|
surrogate marker |
3 |
|
transient ischemic attack |
3 |
|
v-net |
3 |
|
angioplasty |
2 |
|
aquaporin 4 |
2 |
|
atherosclerosis. |
2 |
|
autoimmunity |
2 |
|
cardiovascular system - diseases. |
2 |
|
cognitive impairment |
2 |
|
diffusion-weighted imaging |
2 |
|
direct oral anticoagulants |
2 |
|
ectopic lymphoid structures |
2 |
|
functional prediction |
2 |
|
germinal center |
2 |
|
magnetic resonance imaging |
2 |
|
neuroimaging |
2 |
|
neuromyelitis optica spectrum disorder |
2 |
|
oral anticoagulant |
2 |
|
perivascular spaces |
2 |
|
prevalence |
2 |
|
prospective studies |
2 |
|
rich-club organization |
2 |
|
small vessel disease |
2 |
|
stroke recovery |
2 |
|
strokebleeding |
2 |
|
structural network |
2 |
|
thrombectomy |
2 |
|
vascular dementia |
2 |
|
adenocarcinoma - diagnosis - secondary |
1 |
|
adolescent |
1 |
|
adult |
1 |
|
blood biomarkers |
1 |
|
brain atherosclerosis |
1 |
|
brain hemorrhage |
1 |
|
brain ischemia |
1 |
|
carotid pulsatility |
1 |
|
causal inference |
1 |
|
cerebrovascular accident |
1 |
|
cerebrovascular disease |
1 |
|
child |
1 |
|
functional recovery |
1 |
|
hemorrhagic stroke |
1 |
|
ischemic attack, transient - diagnosis |
1 |
|
ischemic attack, transient - therapy |
1 |
|
mean corpuscular volume |
1 |
|
mendelian randomization |
1 |
|
middle cerebral artery |
1 |
|
molecular biomarkers |
1 |
|
multimodal biomarkers |
1 |
|
muscle neoplasms - diagnosis - secondary |
1 |
|
muscle, skeletal |
1 |
|
neurophysiology |
1 |
|
pathologic constriction |
1 |
|
red blood cell distribution width |
1 |
|
stroke - diagnosis |
1 |
|
stroke - therapy |
1 |
|
tomography, x-ray computed |
1 |
